Our Pipeline: Initial Oncology Drug Pipeline
Merck Preclinical Study Reports 658% increase in STING Agonist to tumor with Vesselon's Drug

Clinical Pipeline


Our scalable platform can create an endless stream of acoustically active drugs at low R&D cost and minimal regulatory risk.

Initial Oncology Drug Pipeline

Preclinical Phase 1 Phase 2 Phase 3

Recurrent, Metastatic Head and Neck Squamous Cell Cancer, 1st Line with Keytruda®


Pancreatic Ductal Adenocarcinoma, 2nd Line, with Keytruda®

SonoLeukin is a conjugation of unaltered IL-2 without synthetic modifications encapsulated within our acoustically active lipid microspheres. IL-2 is protected while in circulation to reduce toxicity and prevent degradation. Ultrasound beam directs SonoLeukin to tumor so that micro-doses of exogenous IL-2 are delivered only to the tumor for immune modulation. Permeability also enhances biodistribution of other drugs used in combination.

Relapsed & Refractory High-Risk Pediatric Neuroblastoma, with Anti-GD-2

SonoVastin is a conjugation of bevacizumab encapsulated within our acoustically active lipid microspheres. Bevacizumab is protected while in circulation to reduce toxicity and prevent degradation. Ultrasound beam directs SonoVastin to tumor so that micro-doses of bevacizumab are delivered into the tumor interstitial space for enhanced antiangiogenesis. Permeability also enhances biodistribution of other drugs used in combination.

Recurrent, Metastatic Head and Neck Squamous Cell Cancer, 2nd Line Monotherapy


Pancreatic Ductal Adenocarcinoma, 2nd Line Monotherapy

SonoVec is a conjugation of Vesselon’s proprietary, patented Ad5/3-C-RGD D24 oncolytic adenovirus (OV). The OV is protected while in circulation to reduce immunogenic response and allow multiple systemic injections. Ultrasound beam directs SonoVec to tumor so that OV is delivered only to the tumor. First trials will be un-armed but subsequent versions will be armed with multiple transgenes for various indications. Permeability also enhances biodistribution of other drugs used in combination.

First Acoustically Active Drug: SonoLeukin™ (Unaltered IL-2)

Unaltered IL-2 With No Synthetic Modifications

Imagent® Interleukin-2 SonoLeukin™
Vesselon’s FDA-Approved acoustically active lipid microsphere Unaltered aldesleukin Acoustically active unaltered aldesleukin

1/20,00th of High Dose IL-2

Solves Toxicity

Micro-dose only delivered to tumor safe outpatient treatment

Solves
Clinical Risk

IL-2 is unaltered and fully active and does not rely on synthetic modifications

Solves Targeting

Ultrasound beam directs drug to tumor

Novel Ad5/3-C-RGD D24 Oncolytic Adenovirus

Intratumoral Injection

Ad5/3-C-RGD D24

Un-Armed
No Transgenes

Armed With
Selected Genes

Systemic Injection

SonoVec™

Unarmed and

encapsulated

Armed and

encapsulated

Solves

Immunogenicity

Protected virus does not stimulate immune response or sequester in liver

Solves Targeting

No need for surgical intratumoral injections